Full-Time
Nurse Consultant
Posted on 9/17/2025
BrightSpring Health Services
10,001+ employees
Home-based and community health services, pharmacy
Compensation Overview
$32k - $35k/yr
Royse City, TX, USA + 4 more
More locations: Garland, TX, USA | Forney, TX, USA | Dallas, TX, USA | Richardson, TX, USA
In Person
 Medical, Clinical & Veterinary (1) |
|---|
- Licensed Nurse (Licensed Vocensed Practical Nurse) or National Certified Pharmacy Technician with minimum of 1 year of experience in long-term care pharmacy or long-term care facility
- 1 year of experience practicing in an LTC nursing facility or pharmacy
- Active LPN licensure in the state of employment or National Pharmacy Technician licensure
- Intermediate computer skills; proficient with Microsoft Office products
- Travel requirement: 75% travel
- Reviews nursing home medication pass process and provides feedback
- Performs MAR-Med Card audits, Med Records audits, Med Cart Audits, Med Room Audits, and 3-way audits in assigned facilities
- Performs new business start-up implementations when necessary
- Performs mock surveys
- Understands customer issues and challenges; quickly and effectively provides a plan for resolution
- Acts as a performance improvement resource for the pharmacy
- Develops and maintains relationships with professional organizations and national/state agencies to enhance knowledge base relative to pharmaceutical therapies and education
- Performs other tasks as assigned
- 2+ years of experience in LTC Pharmacy
- Knowledge of industry related federal/state regulations preferred
BrightSpring Health Services provides home and community-based health care through two main operations: Pharmacy and Provider. In Pharmacy, it offers services for patients with complex and chronic conditions, including specialty, infusion, and community pharmacy solutions. In Provider, it delivers home health, behavioral health, hospice care, and services for intellectual and developmental disabilities. The company uses an integrated care model that connects pharmacy services with in-home care across its network to support patients, families, and managed care organizations. Revenue comes from reimbursed services paid by Medicare, Medicaid, and private insurers. Its goal is to coordinate ongoing, in-home and community-based care across a continuum—from pharmacy support to direct care—ensuring coordinated, patient-centered services for individuals with complex or chronic needs.
Company Size
10,001+
Company Stage
Post IPO Equity
Headquarters
Louisville, Kentucky
Founded
1974
Simplify's Take
What believers are saying
- Q1 2026 revenue hit $3.61B, up 26%, raising full-year guidance to $14.98B.
- Amedisys and LHC acquisitions add 107 locations, contributing $30M EBITDA in 2026.
- Sevita sale yields $811M cash for debt reduction and $2B M&A through 2028.
What critics are saying
- Money Message ransomware stole 2M records including SSNs in March 2023 breach.
- DOJ fined ResCare in October 2019 for fake Medicaid revaluations from 2009-2014.
- Pomerantz investigates securities fraud by BrightSpring officers as of 2026.
What makes BrightSpring Health Services unique
- BrightSpring integrates specialty pharmacy with home health for complex chronic care patients.
- PharMerica dispenses 40 million prescriptions annually to 4 million patients.
- Provider services target intellectual disabilities via home-based behavioral health.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Company News
BrightSpring Health Services announced the resignation of Robert Barnes as President of ResCare Community Living on 30 March 2026, stating it was not due to any disagreement over operations or policies. The company's shares rose 5.2% following upbeat analyst reports from its investor day. Management unveiled ambitious long-term organic EBITDA growth targets of 15% to 20% annually through 2028, alongside AI-driven efficiency plans for its home and community-based care platform. The narrative projects $16.8 billion in revenue and $361.8 million in earnings by 2028, requiring 10.1% yearly revenue growth. Investors remain focused on whether BrightSpring can balance acquisition-driven expansion and technology investment whilst managing its substantial debt load and regulatory exposure.
BrightSpring Health Services has seen its stock price surge 43.1% over the past six months to $42.32 per share, driven by strong quarterly results. The healthcare services company, founded in 1974, offers home health care, hospice, neuro-rehabilitation and pharmacy services. BrightSpring's revenue grew at an 18.3% compound annual growth rate over the past five years, outpacing the healthcare sector average. Analysts forecast 15% revenue growth over the next 12 months, though this represents a deceleration from its recent 20.9% annual rate. However, the company's five-year average return on invested capital of 4.9% falls below the typical cost of capital for healthcare firms, suggesting historically mediocre capital efficiency. The stock currently trades at 27.7× forward price-to-earnings ratio.
BrightSpring Health Services has raised questions about its valuation after trading at 24.5 times forward earnings following strong 2025 performance. The company reported fourth-quarter revenue of $3.55 billion, up 29.3% year-over-year, with adjusted EBITDA rising 40.7% to $184 million. For 2026, management guided revenue between $14.45 billion and $15 billion, representing 11.9% to 16.2% growth, whilst adjusted EBITDA is expected to grow faster at 23% to 28%, indicating margin expansion. However, the company faces approximately $600 million in revenue headwinds from Inflation Reduction Act impacts and brand-to-generic conversions. The valuation hinges on whether BrightSpring can deliver sequential profitability improvements throughout the year despite policy and product-mix pressures affecting headline revenue growth.
BrightSpring Health Services led senior health stocks in Q4 earnings, reporting revenues of $3.55 billion, up 16.3% year on year and beating analyst expectations by 5%. The company delivered strong full-year EBITDA guidance. In contrast, Chemed posted the weakest performance, with revenues of $639.3 million falling 3% short of expectations. The company missed both revenue and full-year EPS guidance estimates, sending shares down 19.2% to $377.07. The seven senior health, home health and hospice stocks tracked reported slower Q4 results overall, with revenues beating consensus estimates by just 1.1%. Share prices have declined an average of 9.6% since earnings releases. The sector faces headwinds from labour shortages and wage inflation whilst benefiting from an ageing population and growing preference for in-home care.
BrightSpring Health Services outlined its growth strategy at an investor day, highlighting a shift towards core home-and-community clinical services. The company's planned community-living divestiture will close soon to boost cash flow and support integrated care initiatives. BrightSpring reported significant deleveraging from approximately 4.5x post-IPO to 2.99x (2.6x pro forma), with leverage expected to fall below 2x in 2026. The company reiterated 2026 guidance of $14.45–$15.0 billion revenue and $760–$790 million adjusted EBITDA, whilst targeting 15–20% organic adjusted EBITDA compound annual growth for 2026–2028. The healthcare services provider has at least $2 billion available for acquisitions through 2028. Its operations include dispensing over 40 million prescriptions annually through PharMerica, serving more than 4 million patients, with recent branch integrations expected to add approximately $30 million of EBITDA.